Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) received a $27.00 price target from Janney Montgomery Scott in a research note issued on Thursday. The firm presently has a “sell” rating on the stock. Janney Montgomery Scott’s target price points to a potential downside of 32.92% from the company’s previous close.

Other research analysts have also issued reports about the stock. Canaccord Genuity reiterated a “buy” rating and issued a $56.00 target price on shares of Pacira Pharmaceuticals in a research report on Monday, July 31st. Royal Bank Of Canada set a $58.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, July 30th. Mizuho reiterated a “buy” rating and issued a $54.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 26th. HC Wainwright set a $59.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Needham & Company LLC initiated coverage on shares of Pacira Pharmaceuticals in a research report on Tuesday, August 22nd. They issued a “buy” rating and a $55.00 target price for the company. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $49.71.

Pacira Pharmaceuticals (NASDAQ:PCRX) traded up $0.75 during trading on Thursday, hitting $40.25. 710,957 shares of the stock traded hands, compared to its average volume of 843,788. Pacira Pharmaceuticals has a 52-week low of $29.81 and a 52-week high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The firm had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $68.99 million. During the same quarter in the prior year, the firm posted $0.20 earnings per share. The business’s quarterly revenue was down 1.6% on a year-over-year basis. sell-side analysts anticipate that Pacira Pharmaceuticals will post -0.87 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Pacira Pharmaceuticals, Inc. (PCRX) Given a $27.00 Price Target by Janney Montgomery Scott Analysts” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/18/pacira-pharmaceuticals-inc-pcrx-given-a-27-00-price-target-by-janney-montgomery-scott-analysts.html.

In other news, CEO David M. Stack sold 58,885 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the completion of the transaction, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at $6,102,347.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Paul J. Hastings sold 1,044 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total transaction of $37,740.60. Following the transaction, the director now directly owns 3,518 shares of the company’s stock, valued at $127,175.70. The disclosure for this sale can be found here. Corporate insiders own 6.60% of the company’s stock.

Several large investors have recently modified their holdings of PCRX. BlackRock Inc. raised its stake in shares of Pacira Pharmaceuticals by 28,922.7% during the first quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock valued at $145,180,000 after acquiring an additional 3,172,817 shares during the last quarter. HealthCor Management L.P. raised its stake in shares of Pacira Pharmaceuticals by 63.1% during the second quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock valued at $85,564,000 after acquiring an additional 693,799 shares during the last quarter. Eaton Vance Management bought a new position in shares of Pacira Pharmaceuticals during the second quarter valued at about $19,519,000. Mesirow Financial Investment Management Equity Management bought a new position in shares of Pacira Pharmaceuticals during the third quarter valued at about $14,671,000. Finally, Stonepine Capital Management LLC bought a new position in shares of Pacira Pharmaceuticals during the third quarter valued at about $14,089,000. 99.64% of the stock is owned by hedge funds and other institutional investors.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.